Snapshot
A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.
The Asia-Pacific Biologics and Biosimilars market will reach xxx Million USD in 2018 and CAGR xx% 2018-2023. The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Biologics and Biosimilars by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.
Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.):
Antibody
Hormone
Growth Factors
Others




Company Coverage (Sales Revenue, Price, Gross Margin, Main Products etc.):
Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
United Laboratories
Application Coverage (Market Size & Forecast, Different Demand Market by Region, Main Consumer Profile etc.):
Tumor
Diabetes
Cardiovascular
Hemophilia
Others
Region Coverage (Regional Production, Demand & Forecast by Regions etc.):
China
Japan & Korea
India
Southeast Asia
Oceania